Form 4: Edwards Lifesciences Executive Exercises Options and Sells Shares Under 10b5-1 Plan

Donald E. Bobo Jr., a CVP at Edwards Lifesciences, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• On September 11, 2024, Donald E. Bobo Jr., CVP of Strategy/Corporate Development at Edwards Lifesciences Corp, exercised options to acquire 5,000 shares of common stock at a price of $45.2767 per share.
• Simultaneously, Bobo sold 5,000 shares of common stock at a weighted average price of $66.7651 per share, with prices ranging from $66.495 to $67.000.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 14, 2023.
• Following these transactions, Bobo directly owns 46,935.7184 shares of common stock and indirectly owns 38,616.6145 shares through a 401(k) and 135,152 shares through a trust.
• Bobo also continues to hold options for 45,500 shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing executive stock transactions. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are often related to compensation and personal financial planning. The use of 10b5-1 plans allows insiders to trade company stock without being accused of insider trading, as the trades are pre-planned and executed according to a predetermined schedule.

Comparison to Industry Standards

• Executive compensation practices, including stock options and trading plans, are common across the medical device industry.
• Companies like Medtronic, Abbott, and Boston Scientific also utilize stock options as part of their executive compensation packages.
• The specifics of these plans, such as vesting schedules and exercise prices, can vary significantly between companies.

Key Dates